Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanchi powder, also known as Sanqi powder, is a traditional Chinese medicine (TCM) derived from the roots of *Panax notoginseng*. It is being evaluated by the Xiyuan Hospital of China Academy of Chinese Medical Sciences for the treatment of gastric premalignant lesions (GPL) in patients with chronic atrophic gastritis. In clinical trial settings, it is often administered as part of the Jianpi Huoxue Recipe in combination with Moluodan. The therapeutic mechanism of Sanchi powder involves inhibiting the growth of premalignant cells and inducing apoptosis by modulating apoptosis-related genes such as Bcl-2, Bax, and p21WAF1, as well as regulating the abnormal expression of oncogenes like EGFR in the gastric mucosal epithelial cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sanchi powder.